Mifepristone

225 interactions 13 explained in plain English
Also sold as: Korlym Mifeprex
Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jul 4, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Hydrocortisone Neratinib Ciclesonide Oral Inhalation Diflorasone Topical Clindamycin Topical Desonide
69 Contraindicated 139 Major 17 Moderate
All (225) Contraindicated (69) Major (139) Moderate (17)

Major

Mifepristone Mitapivat Aqvesme Increased CYP3A4 substrates exposure, reduced miFEPRIStone exposure and reduced efficacy of miFEPRIStone Details Mifepristone Morphine Injection Astramorph® PF Increased morphine exposure and an increased risk of morphine-related adverse effects (hypotension, respiratory depression, profou... Details Mifepristone Moxifloxacin Avelox Increased risk of QT interval prolongation Details Mifepristone Moxifloxacin Injection Avelox Increased risk of QT interval prolongation Details Mifepristone Moxifloxacin Ophthalmic Moxeza® Increased risk of QT interval prolongation Details Mifepristone Nafcillin Injection Unipen® Injection Reduced miFEPRIStone exposure and reduced efficacy of miFEPRIStone Details Mifepristone Naldemedine Symproic Increased CYP3A4 substrate exposure Details Mifepristone Nateglinide Starlix® Increased CYP3A4 substrate exposure Details Mifepristone Nevirapine Viramune Increased CYP3A4 substrate exposure Details Mifepristone Nifedipine Adalat® Increased NIFEdipine exposure and an increased risk of hypotension, bradycardia, or acute renal injury Details Mifepristone Nintedanib Ofev Increased CYP3A4 substrate exposure Details Mifepristone Nisoldipine Sular Increased CYP3A4 substrate exposure Details Mifepristone Octreotide Bynfezia An increased risk of QT interval prolongation Details Mifepristone Octreotide Injection Bynfezia An increased risk of QT interval prolongation Details Mifepristone Ofloxacin Floxin® An increased risk of QT interval prolongation Details Mifepristone Ofloxacin Ophthalmic Ocuflox An increased risk of QT interval prolongation Details Mifepristone Ofloxacin Otic Floxin® Otic An increased risk of QT interval prolongation Details Mifepristone Olodaterol Oral Inhalation Striverdi An increased risk of QT interval prolongation and an increased risk of ventricular arrhythmias Details Mifepristone Oxaliplatin Injection Eloxatin® Increased risk of QT-interval prolongation Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.